PREMIER partners will present at SETAC Europe: don´t miss out!27 April 2022 - 15:10
Meet our Scientific Advisory Board: Interview with Marlene Ågerstrand19 April 2022 - 16:30
Exploring the feasibility of implementing the design of greener Active Pharmaceutical Ingredients by interviewing experts from pharma industry5 April 2022 - 15:16
PREMIER celebrates its 4th General Assembly 1 April 2022 - 16:32
Prioritization and selection of APIs using a risk-based approach2 March 2022 - 17:06| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Prioritization and selection of APIs using a risk-based approach
blogBy Cristiana Cannata, PhD researcher in Environmental Science at Radboud University (Nijmegen, The Netherlands) & contributor of PREMIER WP1.2 There are more than 1500 active pharmaceutical ingredients (APIs) on the European market. Residues of these APIs can eventually reach the environment and given the enormous number of human medicines being used, it is unclear which […]
Ecotoxicity testing: guidelines and evaluation
blogBy Alice Marshall, PhD researcher in Environmental Toxicology at University of York & contributor of PREMIER WP2.1; and Caroline Moermond, Sr Policy Advisor at the National Institute for Public Health and the Environment (RIVM), lead of PREMIER WP4 and contributor of WP3. With the continuous development of new and existing pharmaceuticals, investigation into the environmental legacy of active pharmaceutical […]
PREMIER workshop on ‘What constitutes a more environmentally friendly API?’
blogBy Dr. Caroline Moermond, The Dutch National Institute for Public Health and the Environment (RIVM) On February 2, 2021 a consortium-wide workshop was held with more than 20 participants from all PREMIER work packages. They discussed what are the characteristics that make an active pharmaceutical ingredient (API) to be an issue for the environment. […]